The bidirectional predictive association between methamphetamine use and depression

BACKGROUND AND AIMS: Co-occurrence of methamphetamine dependence and depression is high, though the direction of this temporal relationship is unclear. We investigated the direction of the temporal relationship between methamphetamine use and depression. DESIGN: A longitudinal random-intercept cross-lagged panel model analysis was conducted using 12 contiguous weeks of data from a randomised controlled trial (ACTRN12618000366257). SETTING: Melbourne, Geelong and Wollongong, Australia. PARTICIPANTS: 153 adult participants dependent on methamphetamine. MEASUREMENTS: Each week, days of methamphetamine use in the past week were assessed using the Timeline Followback, and clinically significant symptoms of depression were defined as a score of 4 or greater on the Brief Psychiatric Rating Scale depression item. RESULTS: Relative to their average, if an individual increased their methamphetamine use in one week, their probability of experiencing clinically significant depressive symptoms increased the following week [estimate = 0.271, 95% confidence interval (CI) = 0.177-0.365, P < 0.001]. Additionally, if an individual's probability of experiencing clinically significant depressive symptoms increased in one week above their average, their subsequent week's methamphetamine use increased (estimate = 0.414, 95% CI = 0.291-0.537, P < 0.001). SUMMARY: There appears to be evidence of a bidirectional relationship between days of methamphetamine use and clinically significant depressive symptoms within a weekly timeframe.

Authors

Institutions

Publication Details

Journal
Addiction
Published
2026-10-24
DOI
https://doi.org/10.1111/add.70668
Primary Topic
Substance Abuse Treatment and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The bidirectional predictive association between methamphetamine use and depression

Louisa J Degenhardt, Gregory Leigh Carter, Philip James Clare, Shalini Arunogiri et al.
Addiction
Substance Abuse Treatment and Outcomes
article

The bidirectional predictive association between methamphetamine use and depression

Louisa J Degenhardt, Gregory Leigh Carter, Philip James Clare, Shalini Arunogiri, Olivia May Dean, Dan Ian Lubman, Rebecca McKetin, Lucy Thi Tran, Alyna Turner, Peter J. Kelly, Michael P. Berk
article en

Abstract

BACKGROUND AND AIMS: Co-occurrence of methamphetamine dependence and depression is high, though the direction of this temporal relationship is unclear. We investigated the direction of the temporal relationship between methamphetamine use and depression. DESIGN: A longitudinal random-intercept cross-lagged panel model analysis was conducted using 12 contiguous weeks of data from a randomised controlled trial (ACTRN12618000366257). SETTING: Melbourne, Geelong and Wollongong, Australia. PARTICIPANTS: 153 adult participants dependent on methamphetamine. MEASUREMENTS: Each week, days of methamphetamine use in the past week were assessed using the Timeline Followback, and clinically significant symptoms of depression were defined as a score of 4 or greater on the Brief Psychiatric Rating Scale depression item. RESULTS: Relative to their average, if an individual increased their methamphetamine use in one week, their probability of experiencing clinically significant depressive symptoms increased the following week [estimate = 0.271, 95% confidence interval (CI) = 0.177-0.365, P < 0.001]. Additionally, if an individual's probability of experiencing clinically significant depressive symptoms increased in one week above their average, their subsequent week's methamphetamine use increased (estimate = 0.414, 95% CI = 0.291-0.537, P < 0.001). SUMMARY: There appears to be evidence of a bidirectional relationship between days of methamphetamine use and clinically significant depressive symptoms within a weekly timeframe.

Addiction
The University of Sydney (AU), The Royal Melbourne Hospital (AU), Barwon Health (AU), The University of Melbourne (AU), University of Wollongong (AU), Florey Institute of Neuroscience and Mental Health (AU), UNSW Sydney (AU), Cooperative Trials Group for Neuro-Oncology (AU), Eastern Health (AU), Orygen (AU), Monash Health (AU), National Drug and Alcohol Research Centre (AU), University of Newcastle Australia (AU)
Openalex Percentile: Top 12%
Substance Abuse Treatment and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon